Guardant Health (GH)
(Delayed Data from NSDQ)
$27.10 USD
-0.37 (-1.35%)
Updated May 31, 2024 04:00 PM ET
After-Market: $27.11 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
GH 27.10 -0.37(-1.35%)
Will GH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for GH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GH
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
Stock Market News for May 13, 2024
GH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Other News for GH
Guardant Health Named to TIME100 Most Influential Companies
Guardant Health Enhances Executive Severance and Vesting Provisions
Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
Cathie Wood-Led Ark Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares